stockportfolio.pro
Stocks / EBS vs OVID
EBS vs OVID
Emergent BioSolutions Inc. and Ovid Therapeutics Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Emergent BioSolutions Inc. (EBS) | Ovid Therapeutics Inc. (OVID) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $705.20M | $7.25M |
| Net income (latest FY) | $52.60M | $-17.41M |
| Revenue growth (5y CAGR) | -14.9% | -10.5% |
| Net margin | 7.5% | -240.1% |
| Return on equity | 10.1% | -13.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 1 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EBS — free Open OVID — freeFrequently asked questions
Which is bigger, EBS or OVID?
Emergent BioSolutions Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, EBS or OVID?
Over the last five fiscal years, Ovid Therapeutics Inc. grew revenue faster — -10.5%/yr versus -14.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.